Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Antibe Therapeutics Inc(Pre-Merger) T.ATE


Primary Symbol: ATBPF

Healthcare
Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.


GREY:ATBPF - Post by User

Antibe Therapeutics Inc(Pre-Merger)
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(892)
•••
Post by Duster340on Mar 06, 2021 10:57am
138 Views
Post# 32736019

Price target revised slightly lower

Price target revised slightly lower
 

 Stock Forecast & Price Targets

Showing:

Analyst Rating Consensus

Strong Buy

Based on 3 Analyst Ratings

  • 3 Buy
  • 0 Hold
  • 0 Sell

Based on 3 analysts offering stock ratings for Antibe Therapeutics in the last 3 months (by analysts ranked 0 to 5 stars).

Analyst Price Target on TSE:ATE

C$13.46
 (187.69% Upside)

Based on 3 analysts offering 12 month price targets for Antibe Therapeutics in the last 3 months. The average price target is C$13.46 with a high forecast of C$15.95 and a low forecast of C$9.97. The average price target represents a 187.69% increase from the last price of C$4.68.

Past 12 Months     12 Months ForecastMar2020JunSepDecMar202136.7510.5014.2518Mar2022
 
Average
C$13.46
Low
C$9.97
High
C$15.95

Detailed list of analyst forecasts

 Stock Forecast & Price Targets

Showing:

Analyst Rating Consensus

Strong Buy

Based on 3 Analyst Ratings

  • 3 Buy
  • 0 Hold
  • 0 Sell

Based on 3 analysts offering stock ratings for Antibe Therapeutics in the last 3 months (by analysts ranked 0 to 5 stars).

Analyst Price Target on TSE:ATE

C$13.46
 (187.69% Upside)

Based on 3 analysts offering 12 month price targets for Antibe Therapeutics in the last 3 months. The average price target is C$13.46 with a high forecast of C$15.95 and a low forecast of C$9.97. The average price target represents a 187.69% increase from the last price of C$4.68.

Past 12 Months     12 Months ForecastMar2020JunSepDecMar202136.7510.5014.2518Mar2022
 
Average
C$13.46
Low
C$9.97
High
C$15.95

Detailed list of analyst forecasts

<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities